MNKD News & Analysis
3 articles
Market Mood
MannKind (MNKD) Stock Rating Reiterated Following FDA Approval
H.C. Wainwright has reiterated its stock rating for MannKind (MNKD) following the FDA's approval of a new treatment. This approval is significant as it marks a potential milestone for the company's product pipeline and could influence investor sentiment. The news may affect MannKind's trading volume and overall market performance. Investors should monitor MannKind's stock closely as the FDA approval could lead to increased demand for its products.
Read More: MannKind (MNKD) Stock Rating Reiterated Following FDA Approval
MannKind Corp (MNKD) Form 4 Filed on July 17
MannKind Corp (MNKD) filed a Form 4 on July 17, documenting insider transactions. The filing provides detailed information about stock trades made by company insiders, which can indicate their sentiment about the company's prospects and performance. Such filings are typically scrutinized by investors for potential signals regarding the company's outlook and stock valuation. This filing is relevant for investors as it may influence their perception of insider confidence in MannKind's future.
Read More: MannKind Corp (MNKD) Form 4 Filed on July 17
MannKind Corporation (MNKD) Price Target Raised to $11 by Wells Fargo
On June 1, Wells Fargo increased its price target for MannKind Corporation (MNKD) from $10 to $11, maintaining an Overweight rating. This adjustment is attributed to the recent FDA approval of Afrezza Inhalation Powder for pediatric patients aged 6 and older. MannKind also indicated the possibility of receiving up to $35 million in development milestones along with a 10% royalty on net sales. These developments enhance MNKD's potential in the biopharmaceutical market, particularly in treating diabetes in children and adolescents.
Read More: MannKind Corporation (MNKD) Price Target Raised to $11 by Wells Fargo